Clinical Trial Detail

NCT ID NCT03257722
Title Pembrolizumab + Idelalisib for Lung Cancer Study
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Zhonglin Hao
Indications

lung non-small cell carcinoma

Therapies

Idelalisib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.